Automation of an integrated micro‐scale platform for monoclonal antibody process development by incorporation of a depth filter mimic
Biotechnology Progress · 2026
DOI: 10.1002/btpr.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2026. Verfasst von Paras Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Engineering, University College London, London, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Filtration. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, CSL Behring Innovation GmbH.
Abstract (Originalsprache)
High throughput process development (HTPD) has been widely adopted for efficient development and optimization of chromatographic operations in monoclonal antibody (mAb) purification. However, the integration of non‐chromatographic unit operations, particularly depth filtration following protein A chromatography, which is essential for the removal of process‐ and product‐related impurities prior to the ion exchange chromatography (IEX) operations, remains a challenge due to the absence of commercially available micro‐scale depth filtration tools. This limits the integration of this unit operation within the purification sequence, restricting the analysis of process interactions and overall process understanding. In this study, a micro‐scale HTPD platform was designed and evaluated to enable integration of a depth filtration mimic, Sartobind® Q anion exchange adsorber, within a mAb purification sequence. This was achieved by translating laboratory‐scale protocols to the micro‐scale using workflow design tools and executed on an automated liquid handling system. Step yields and impurity clearance were assessed to confirm the equivalence of scale‐down. The Sartobind® Q membrane achieved effective removal of host cell DNA (hcDNA), while subsequent IEX operations removed host cell proteins (HCPs) and high molecular weight components (HMWC), meeting target product quality specifications. The platform demonstrated robustness across varying impurity profiles, supporting its applicability for diverse process intermediates. Comparative analysis with laboratory‐scale operations confirmed the performance and scalability of the micro‐scale system, reducing the total run time by greater than 50%. The integrated HTPD platform offers a resource‐efficient, scalable approach for comprehensive mAb purification process development and is suitable for developability assessments during early‐stage development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemical Engineering, University College London, London, UK.
- CSL Behring Innovation, Marburg, Germany.
ORCID-Profile: Paras Sharma
Förderung
- Engineering and Physical Sciences Research Council
- CSL Behring Innovation GmbH
Zitieren
APA
Sharma, P., Sebastian, P., Robbel, L., Schmitt, M., & Bracewell, D. G. (2026). Automation of an integrated micro‐scale platform for monoclonal antibody process development by incorporation of a depth filter mimic. Biotechnology Progress. https://doi.org/10.1002/btpr.70077
Vancouver
Sharma P, Sebastian P, Robbel L, Schmitt M, Bracewell DG. Automation of an integrated micro‐scale platform for monoclonal antibody process development by incorporation of a depth filter mimic. Biotechnology Progress. 2026. doi:10.1002/btpr.70077
BibTeX
@article{Sharma2026,
author = {Sharma, Paras and Sebastian, Petra and Robbel, Lars and Schmitt, Michael and Bracewell, Daniel G},
title = {Automation of an integrated micro‐scale platform for monoclonal antibody process development by incorporation of a depth filter mimic},
journal = {Biotechnology Progress},
year = {2026},
doi = {10.1002/btpr.70077}
}
EUVIMED